Biological therapies for rheumatoid arthritis: An overview for the clinician

Kate E. Findeisen; Julia Sewell; Andrew J.K. Ostor

doi:10.2147/BTT.S252575

Biological therapies for rheumatoid arthritis: An overview for the clinician

Kate E. Findeisen, Julia Sewell, Andrew J.K. Ostor^*

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

37 Citations (Scopus)

Abstract

Rheumatoid arthritis (RA) is a disease characterised by inflammation of synovial joints and poses a substantial healthcare burden on both the individual and society. One of the most significant shifts in the RA therapeutic landscape has occurred with the introduction of biological disease modifying anti-rheumatic drugs (bDMARDs). There are five classes of bDMARDs currently available, each with a different molecular target and subtle differences in their efficacy and safety profile. This review also describes the “real-world” use of bDMARDs and how they fit into the overall RA treatment guidelines.

Original language	English
Pages (from-to)	343-352
Number of pages	10
Journal	Biologics: Targets and Therapy
Volume	15
DOIs	https://doi.org/10.2147/BTT.S252575
Publication status	Published - 2021
Externally published	Yes

Access to Document

10.2147/BTT.S252575

Cite this

@article{64f62fcfe0ea461288e5f73678017c6d,

title = "Biological therapies for rheumatoid arthritis: An overview for the clinician",

abstract = "Rheumatoid arthritis (RA) is a disease characterised by inflammation of synovial joints and poses a substantial healthcare burden on both the individual and society. One of the most significant shifts in the RA therapeutic landscape has occurred with the introduction of biological disease modifying anti-rheumatic drugs (bDMARDs). There are five classes of bDMARDs currently available, each with a different molecular target and subtle differences in their efficacy and safety profile. This review also describes the “real-world” use of bDMARDs and how they fit into the overall RA treatment guidelines.",

keywords = "BDMARDs, Biological therapies, Rheumatoid arthritis",

author = "Findeisen, {Kate E.} and Julia Sewell and Ostor, {Andrew J.K.}",

note = "Publisher Copyright: {\textcopyright} 2021 Findeisen et al.",

year = "2021",

doi = "10.2147/BTT.S252575",

language = "English",

volume = "15",

pages = "343--352",

journal = "Biologics: Targets and Therapy",

issn = "1177-5475",

publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Biological therapies for rheumatoid arthritis

T2 - An overview for the clinician

AU - Findeisen, Kate E.

AU - Sewell, Julia

AU - Ostor, Andrew J.K.

PY - 2021

Y1 - 2021

N2 - Rheumatoid arthritis (RA) is a disease characterised by inflammation of synovial joints and poses a substantial healthcare burden on both the individual and society. One of the most significant shifts in the RA therapeutic landscape has occurred with the introduction of biological disease modifying anti-rheumatic drugs (bDMARDs). There are five classes of bDMARDs currently available, each with a different molecular target and subtle differences in their efficacy and safety profile. This review also describes the “real-world” use of bDMARDs and how they fit into the overall RA treatment guidelines.

AB - Rheumatoid arthritis (RA) is a disease characterised by inflammation of synovial joints and poses a substantial healthcare burden on both the individual and society. One of the most significant shifts in the RA therapeutic landscape has occurred with the introduction of biological disease modifying anti-rheumatic drugs (bDMARDs). There are five classes of bDMARDs currently available, each with a different molecular target and subtle differences in their efficacy and safety profile. This review also describes the “real-world” use of bDMARDs and how they fit into the overall RA treatment guidelines.

KW - BDMARDs

KW - Biological therapies

KW - Rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=85113236544&partnerID=8YFLogxK

U2 - 10.2147/BTT.S252575

DO - 10.2147/BTT.S252575

M3 - Review article

SN - 1177-5475

VL - 15

SP - 343

EP - 352

JO - Biologics: Targets and Therapy

JF - Biologics: Targets and Therapy

ER -

Biological therapies for rheumatoid arthritis: An overview for the clinician

Abstract

Access to Document

Other files and links

Fingerprint

Cite this